---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-004150"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:10:21.881428+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dogwood Therapeutics Q4 2024 net loss $8.2M; cash $14.8M; Halneuron Phase 2b interim data expected Q4 2025

## Summary
- Q4 2024 net loss $8.2M ($6.29/share) vs $1.1M ($1.43/share) in Q4 2023; FY net loss $12.9M ($12.52/share) vs $5.3M ($7.05/share).
- Cash $14.8M at Dec 31, 2024; $4.8M capital raise and conversion of $19.5M debt to equity extend runway through Q1 2026.
- Halneuron Phase 2b CINP trial dosing commenced; interim data readout expected Q4 2025.
- Largest shareholder converted $19.5M loan to equity, strengthening balance sheet.
- Exploring partnerships for IMC-2 (Long-COVID) and IMC-1 (fibromyalgia); update on IMC-1 expected Q2 2025.

## SEC filing metadata
- accession: 0001558370-25-004150
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837025004150/0001558370-25-004150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837025004150/dwtx-20250331x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-004150
- JSON: https://secwatch.observer/filing/0001558370-25-004150.json
- Plain text: https://secwatch.observer/filing/0001558370-25-004150.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.